Despite Wall Street's not-so-positive view of data from Regeneron Pharmaceuticals Inc.'s Phase II trial of its interleukin-1 Trap product in rheumatoid arthritis, the company believes the 200-patient trial demonstrates enough biological effect to forge ahead. (BioWorld Today) Read More